IDEXX Laboratories Inc (IDXX) stock analysis
IDEXX Laboratories Inc (IDXX) clears 2 of this site's 8 mechanical value filters, 5 of 8 Buffett-style checks and 2 of 5 Lynch-style checks. At $566.76 it trades 110.7% above this site's neutral DCF value (a margin of safety of -110.7%). Its earnings quality rates Strong and it returns +2.6% to shareholders net of dilution. Figures are as of October 23, 2026, from SEC filings and market data refreshed weekly; this is educational analysis, not investment advice.
Data as of October 23, 2026. Refreshed weekly from SEC filings and market data.
What does IDEXX do?
IDEXX makes diagnostic tests, instruments and software for veterinarians, including in-clinic analyzers and reference-lab services for pets, and earns recurring revenue from the test supplies those analyzers use.
Brands and businesses it owns
- SNAP
- Catalyst
- ProCyte Dx
What stands out about IDEXX?
- The share price implies 27.3% yearly growth. At $566.76, IDXX's free cash flow of $15.75 per share would have to grow 27.3% a year, fading to 2.5% by year 10, for this site's DCF (10% discount rate) to match the price. This site's baseline starts at 8%, so the price asks for more growth than the baseline. Change the assumptions.
- Misses 4 of the 8 value filters. It fails Trailing P/E < 25 (39.06), PEG Ratio < 1.5 (2.78) and Price/Book < 8 (27.61) and 1 more; the other 2 pass and 2 were not evaluated. See every filter.
- The margin of safety is falling. It went from -95% on Oct 7 to -111% on Oct 23 across 5 weekly readings. See the trend.
- Strongest against peers: return on equity. At 72% (peer median 15%) it ranks 4th of 34 among health care stocks this site tracks. See the ranking.
- Weakest against peers: free-cash-flow yield. At 2.8% (peer median 5.5%) it ranks 31st of 34 among health care stocks this site tracks. See the ranking.
How has IDEXX's share price moved?
The interactive price chart needs JavaScript.
Is IDEXX undervalued? The value diligence check
Every value-investing signal this site computes for this stock, gathered in one place: the same real numbers from the tools below, not a new score.
- Margin of safety (DCF) -110.7%
- P/E vs. its own history 39.1x · near the cheap end Real range: 38.7x–76.5x over 5 years (net income per diluted share from each fiscal year's 10-K, paired with the real closing price at that fiscal year-end).
- Wall St. analyst rating Buy · 4.00/5 21 analysts this month: 7 strong buy, 7 buy, 7 hold, 0 sell, 0 strong sell (Finnhub). Up from 3.95 last month.
- Altman Z″-Score (bankruptcy risk) 10.43 · Safe zone
- Earnings quality (is the profit real?) Strong · all 5 checks clean Beneish M-score −2.51 · accruals −3.7% of assets · 108% of profit arrived as cash · stock comp 1.4% of revenue · share count −1.8% a year. From the latest 10-K (year to Dec 2025) - see the Earnings Quality Screener for how each check is scored.
- Shareholder yield (cash back to owners) +2.6% net Latest fiscal year (2025): dividends 0.0% + buybacks 2.7% − stock comp 0.1%, as a share of today's market cap. Over 14 years its split-adjusted share count fell 30%. See Shareholder Yield Leaders.
- Capital needed to grow (See's test) $1.54 per $1 of new profit · FlightSafety-like Operating profit $418M → $1.2B, capital needed $224M → $1.4B, 2016–2025 (3-year averages); return on capital now 84% before tax. Buffett's See's Candies needed $0.42 per $1 of new profit, FlightSafety $3.20, a typical grower about $5. See Capital-Light Compounders.
- PEG (growth at a reasonable price) 2.78 · Well above fair P/E 39.1× ÷ 14.1% a year of growth behind it. 320th lowest of 447 stocks with a usable PEG. Lynch's fair value is a PEG of 1; a very high PEG usually means almost no growth, a very low one a profit spike. See PEG Ratio Ranking.
- Compounder lenses (4) 3 of 4 · misses price Capital-light growth: cleared; Profit is real: cleared; Cash to owners: cleared; Fair price (PEG): not cleared (PEG 2.78, over 1.5). See Compounders at a Fair Price, which also lets you move the PEG bar.
- Value trap check Clear
- Munger's Inversion Check 2 flags
- Standing vs. sector peers 4 of 6 measures above the median Compared with the 33 other health care stocks this site tracks: 3 in the top third, 2 in the bottom third.
How does IDEXX compare with its peers?
4 of 6 measures sit above the median of the 33 other health care stocks tracked here, 3 in the top third and 2 in the bottom third.
- P/E ratiolower is cheaper · peer median 24.6× 39.1× ✕27th of 32
- Free-cash-flow yieldhigher is cheaper · peer median 5.5% 2.8% ✕31st of 34
- Return on equityhigher is better · peer median 15% 72% ✓4th of 34
- Net marginhigher is better · peer median 9.3% 25.0% ✓4th of 34
- Revenue growthhigher is better, year on year · peer median 8.6% 12.8% ✓10th of 34
- Debt / equitylower is safer · peer median 0.69 0.60 –12th of 34
Peers are the stocks this site tracks in the same sector group, not every listed competitor. The bar runs from the weakest peer (left) to the strongest (right); the tick is the middle. Measures that don't apply to a sector (cash-flow yield for banks, debt for financials) are left out.
What would Buffett & Lynch say?
Buffett's checklist is built around durable, profitable businesses bought at sensible prices, and IDXX doesn't clear enough of it yet. In its favor: IDXX is currently earning a strong return on shareholders' equity, and has kept that profitability up over five years, not just this year, converts sales into profit at healthy margins, has grown earnings per share at a solid clip over five years, and earns many times its interest expense, so debt service isn't a worry. Where it comes up short: IDXX carries more debt relative to equity than he typically tolerates, is trading above what a conservative discounted-cash-flow estimate says it's worth right now, and trades rich relative to owner earnings, the real cash the business could pay out.
- ROE (TTM) > 11% ✓
- ROE (5yr avg) > 11% ✓
- Debt/Equity < 0.5 ✕
- Pretax margin > 15% ✓
- EPS growth (5yr) > 7% ✓
- Interest coverage > 5x ✓
- Trading below intrinsic value (DCF) ✕
- Price vs. owner earnings < 25x ✕
- Bonus: returning capital via buybacks FY2025
Lynch looked for growth stories that weren't overpriced for that growth, and IDXX falls short of his bar. In its favor: IDXX is growing earnings at the steady 10-20% pace of a proper Stalwart, and isn't over-leveraged for a company of its type. Where it comes up short: IDXX fails his signature PEG test, he'd call this pricey for the growth on offer, is asking investors to pay a steep multiple for that growth, and isn't generating free cash flow to match the growth story.
- PEG < 1 ✕
- EPS growth 10%-20% ✓
- Debt/Equity < 0.6 ✓
- P/E < 27 ✕
- Price/FCF < 30 ✕
Quantitative approximations of each investor's documented approach, not endorsed by either investor or their estates - commentary, not this site's actual ranking criteria. Buffett never published a numeric checklist: only 2 of his 8 checks here trace to his own documented concepts ("owner earnings," from his 1986 shareholder letter, and "price is what you pay, value is what you get," his case against fixed P/E/P/B ceilings) - the other 6 (ROE, debt, margins, growth, interest coverage) use commonly-cited thresholds that are not numbers he himself published. The 8 hard filters below (plus the Munger check and Graham margin of safety) are this site's real, mechanical screen and are computed completely independently of the checklists above.
Berkshire Hathaway's own filing
Which of the 8 value filters does IDEXX pass?
- Market Cap > $25B $44.5B
- Trailing P/E < 25 39.06
- PEG Ratio < 1.5 2.78
- Price/Book < 8 27.61
- Price/Sales < 7 9.78
- EPS Growth YoY > -5% +17.6%
- vs 50-day MA (±12%) Not evaluated †
- vs 200-day MA (±12%) Not evaluated †
What is IDEXX's margin of safety?
-95% on 2026-10-07 → -111% on 2026-10-23 (5 weekly readings).
Where is IDEXX in its 52-week range?
What is the short interest in IDEXX?
1,940,639 shares short as of 2026-09-30 (FINRA settlement date). Reported twice a month, so this only changes roughly every two weeks, not daily.
What could go wrong with IDEXX? Munger's inversion check
"Invert, always invert." Instead of reasons to buy, these are reasons to hesitate, not a verdict, and not everything worth knowing about a business.
- Margin of safety, even in the bull case -25%
- Short interest under 5% of float 2.5%
- Passes most of the 6 fundamental filters 2/6 passed
- Price run-up backed by value, not just momentum +12% off 52wk low
- Debt/equity stable since 2019 3.94 → 0.28
Doesn't cover circle of competence, management quality, or accounting concerns: those need judgment, not data.
How much have IDEXX shareholders gained per year?
Earnings growth per share plus dividend.
An earnings-based proxy, not a stock-price total return - it doesn't capture multiple expansion/contraction or reinvested dividends. EPS from IDXX's own 10-K filings; dividend yield is the current trailing yield on today's price, from the same weekly fetch as the rest of this site.
What do IDEXX's 10-year financials show?
From IDXX's own 10-K filings (SEC EDGAR): up to the last 10 fiscal years. Press any year's bars for the exact figures.
Frequently asked questions about IDEXX
What kind of company is IDEXX?
IDEXX makes diagnostic tests, instruments and software for veterinarians, including in-clinic analyzers and reference-lab services for pets, and earns recurring revenue from the test supplies those analyzers use. Brands and businesses it owns include SNAP, Catalyst and ProCyte Dx. This site groups it with Health Care stocks.
Is IDEXX trading above or below its DCF value?
At $566.76, IDXX trades 110.7% above this site's neutral DCF value of $268.94 per share, a margin of safety of −110.7%. That DCF projects free cash flow for 10 years, with growth starting at 8% and fading to 2.5%, discounted at 10%; it is one set of assumptions, not a forecast. Test your own in the Intrinsic Value Calculator.
How many of this site's 8 value filters does IDEXX pass?
IDXX passes 2 of 8. It passes Market Cap > $25B ($44.5B) and EPS Growth YoY > -5% (+17.6%). It misses Trailing P/E < 25 (39.06), PEG Ratio < 1.5 (2.78), Price/Book < 8 (27.61) and Price/Sales < 7 (9.78). vs 50-day MA (±12%) and vs 200-day MA (±12%) were not evaluated, because the moving-average checks only run on stocks that clear the fundamentals first. The 8-filter list shows every stock that passes all of them.
What growth is IDEXX's share price pricing in?
At $566.76, IDXX's free cash flow of $15.75 per share would have to grow 27.3% a year, fading to 2.5% by year 10, for this site's DCF (10% discount rate) to match the price. This site's baseline starts at 8%, so the price asks for more growth than the baseline. Change the assumptions.
Which well-known investors own IDEXX?
Among the investors whose SEC 13F filings this site tracks, Terry Smith (3.9% of the portfolio; trimmed the position) held IDXX as of June 30, 2026. 13F filings cover only US-listed equities and arrive up to 45 days after the quarter ends, so they lag the real portfolios. See Superinvestors.
When does IDEXX report earnings next?
IDEXX's next earnings report is expected on November 2, 2026 before the market opens, with analysts expecting earnings of $3.82 per share. Dates come from the Finnhub earnings calendar and can move. In its last 4 quarters it beat the estimate 4 times, by an average of +4.0%.
Where do these numbers come from?
- Financial statements: IDEXX's 10-K annual report for the year ended Dec 31, 2025, filed Feb 20, 2026 (filing index). Every earlier year in the 10-year financials comes from the company's older 10-K filings, all listed on SEC EDGAR.
- Prices and market data: quotes, P/E and analyst ratings from Finnhub; daily price history and the 52-week range from Twelve Data, both refreshed weekly. Short interest comes from FINRA, reported twice a month.
- How to check a figure: click any number in the card above to see its exact source, and read the Editorial Standards for every rule behind the checks.
About this IDEXX Laboratories Inc analysis
This page shows every value-investing check the site runs on IDEXX Laboratories Inc (IDXX) in one place: the 8 mechanical filters, the Buffett and Lynch checklists, a margin of safety from a disclosed DCF, earnings quality, shareholder yield and how it ranks against its sector peers. The numbers come from SEC filings and public market data, refreshed weekly, and the same rules apply to every stock on the stock list. See Editorial Standards for the sources and the rules, or run your own filters in the stock screener.